Literature DB >> 7511178

An epitope in the V1 domain of the simian immunodeficiency virus (SIV) gp120 protein is recognized by CD8+ cytotoxic T lymphocytes from an SIV-infected rhesus macaque.

A L Erickson1, C M Walker.   

Abstract

Cytotoxic T-lymphocyte (CTL) responses against the external envelope glycoprotein (gp120) of the simian immunodeficiency virus (SIV) were studied in a rhesus macaque infected with SIVmac/239. CD8+ T cells enriched from concanavalin A-stimulated peripheral blood mononuclear cells lysed autologous target cells infected with recombinant vaccinia virus vectors expressing the SIVmac/239 or SIVsm/H4 envelope protein, which share approximately 80% identity in amino acid sequence. A CD8+ CTL line derived by limiting dilution culture of the concanavalin A-stimulated lymphocytes was also specific for the envelope proteins of both SIV isolates. Mapping studies revealed that this cell line recognized an epitope between amino acids 113 and 121 (CNKSETDRW) in the V1 domain of gp120. Amino acid substitutions are observed at positions 116 and 120 among viruses of the SIVsm/mac/human immunodeficiency virus type 2 group, and thus synthetic peptides representing these variants were tested for the ability to sensitize target cells for lysis by the CTL line. Autologous target cells sensitized with a synthetic peptide representing the SIVmac/239 sequence were efficiently killed. In contrast, recognition of target cells was reduced or abolished when peptides representing the amino acid substitutions at position 116 or 120 of other SIVmac, SIVsm, SIVmne, or SIVstm strains were tested. Further studies of CTL responses against this epitope could provide insights into mechanisms of variability within the gp120 V1 domain and its importance in evasion of immunity in infected or vaccinated monkeys.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511178      PMCID: PMC236756     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

2.  The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques.

Authors:  P R Johnson; T E Hamm; S Goldstein; S Kitov; V M Hirsch
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 3.  The simian immunodeficiency viruses.

Authors:  R C Desrosiers
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

4.  Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus.

Authors:  H Kestler; T Kodama; D Ringler; M Marthas; N Pedersen; A Lackner; D Regier; P Sehgal; M Daniel; N King
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

5.  Selective infection of human CD4+ cells by simian immunodeficiency virus: productive infection associated with envelope glycoprotein-induced fusion.

Authors:  S Koenig; V M Hirsch; R A Olmsted; D Powell; W Maury; A Rabson; A S Fauci; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

6.  The gag-specific cytotoxic T lymphocytes in rhesus monkeys infected with the simian immunodeficiency virus of macaques.

Authors:  M D Miller; C I Lord; V Stallard; G P Mazzara; N L Letvin
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

7.  Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes.

Authors:  L Shen; Z W Chen; M D Miller; V Stallard; G P Mazzara; D L Panicali; N L Letvin
Journal:  Science       Date:  1991-04-19       Impact factor: 47.728

8.  Two distinct lymphocyte populations mediate simian immunodeficiency virus envelope-specific target cell lysis.

Authors:  H Yamamoto; M D Miller; D I Watkins; G B Snyder; N E Chase; G P Mazzara; L Gritz; D L Panicali; N L Letvin
Journal:  J Immunol       Date:  1990-12-01       Impact factor: 5.422

9.  Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism.

Authors:  C M Walker; A L Erickson; F C Hsueh; J A Levy
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 10.  Simian immunodeficiency virus-specific cytotoxic T lymphocytes in rhesus monkeys: characterization and vaccine induction.

Authors:  N L Letvin; M D Miller; L Shen; Z W Chen; Y Yasutomi
Journal:  Semin Immunol       Date:  1993-06       Impact factor: 11.130

View more
  5 in total

1.  The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule.

Authors:  M Furchner; A L Erickson; T Allen; D I Watkins; A Sette; P R Johnson; C M Walker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.

Authors:  P Polacino; V Stallard; J E Klaniecki; D C Montefiori; A J Langlois; B A Richardson; J Overbaugh; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

3.  Neuropathogenic SIVsmmFGb genetic diversity and selection-induced tissue-specific compartmentalization during chronic infection and temporal evolution of viral genes in lymphoid tissues and regions of the central nervous system.

Authors:  Aaron B Reeve; Nicholas C Pearce; Kalpana Patel; Katherine V Augustus; Francis J Novembre
Journal:  AIDS Res Hum Retroviruses       Date:  2010-06       Impact factor: 2.205

4.  Inhibition of simian immunodeficiency virus (SIV) replication by CD8(+) T lymphocytes from macaques immunized with live attenuated SIV.

Authors:  M C Gauduin; R L Glickman; R Means; R P Johnson
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

5.  Molecular and biological analyses of quasispecies during evolution of a virulent simian immunodeficiency virus, SIVsmmPBj14.

Authors:  B Tao; P N Fultz
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.